Recent developments in antiandrogens and selective androgen receptor modulators

► Competitive AR antagonists with improved properties are being evaluated for treatment of prostate cancer. ► Novel compounds addressing alternative pockets, the N-terminal domain or the interaction with DNA have been identified. ► Steroidal SARMs are typically being used for treatment of hypogonadism. ► Non-steroidal SARMs are being tested clinically for the indications frailty syndrome and cachexia.